# US 2013/0156757 A1 · Targeting vegf-b regulation of fatty acid transporters to modulate human diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156757 A1
- Document ID: US20130156757A1
- Status: Published application
- Kind: A1
- Application number: 13/744,728
- Filed: 2013-01-18
- Published: 2013-06-20
- Earliest claimed: 2006-05-17
- Assignees: Ludwig Institute for Cancer Research
- Inventors: Ulf Eriksson
- Web page: https://patentgrep.com/patent/US20130156757A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides materials and methods for modulating FATP expression and/or activity in vivo. The materials and methods have numerous diagnostic, prophylactic, and therapeutic applications for various diseases and conditions that are influenced by FATPs, or characterized by excessive or inadequate FATP expression or activity.

## Claims

### Claim at position 1

-38. (canceled)

### Claim 39

A method of treating dyslipidemia in a human subject comprising administering to a human subject in need of such treatment a VEGF-B inhibitor selected from:
(a) an anti-VEGF-B antibody or antigen-binding fragment thereof; and
(b) an anti-sense oligonucleotide that inhibits VEGF-B transcription or translation.

### Claim 40 (depends on 39)

The method of claim 39 wherein the antibody is a monoclonal antibody.

### Claim 41 (depends on 39)

The method of claim 39 wherein the antibody is a humanized antibody.

### Claim 42 (depends on 39)

The method of claim 39 wherein the VEGF inhibitor is an antibody which binds one or both of VEGF-B167 and VEGF-B186, or an antigen binding fragment thereof.

### Claim 43 (depends on 39)

The method of claim 39 wherein said dyslipidemia is hypercholesterolemia or hypertriglyceridemia.

### Claim 44 (depends on 39)

The method of claim 39 wherein the dyslipidemia is a genetic dyslipidemia.

### Claim 45 (depends on 44)

The method of claim 44 wherein the genetic dyslipidemia is selected from the group consisting of Familial Hypercholesterolemia, Familial Defective Apo 100, Familial Hypertriglyceridemia, Familial Apoprotein CII deficiency, Hepatic Lipase Deficiency, Familial Combined Hyperlipidemia Dysbetalipoproteinemia and Familial Lipoprotein Lipase Deficiency.

### Claim 46 (depends on 39)

The method of claim 39 wherein the VEGF-B inhibitor is administered in combination with one or more further pharmacologically active substances for the treatment of dyslipidemia.

### Claim 47 (depends on 46)

The method of claim 46 wherein the VEGF-B inhibitor and the active substance for the treatment of dyslipidemia are administered separately or in the form of a combined product.